Trifluoperazine Hydrochloride

CHEMBL1257040 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
480.4 g/mol
LogP
Phase
4

Trifluoperazine hydrochloride is the hydrochloride salt form of trifluoperazine, a high-potency phenothiazine antipsychotic dopamine D2 receptor antagonist. See trifluoperazine for complete pharmacological details. This salt formulation provides water-soluble form for oral tablet, liquid, and injectable preparations in schizophrenia and anxiety management.

Peso Molecular

480,4000 g/mol

TPSA

35,00 Ų

Mecanismo de Ação

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl

InChI

InChI=1S/C21H24F3N3S.2ClH/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24;;/h2-3,5-8,15H,4,9-14H2,1H3;2*1H

Molecular Formula

C21H26Cl2F3N3S

HBD / HBA

2 / 7

Ligações Rotacionáveis

4

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Trifluoperazine hydrochloride is the hydrochloride salt form of trifluoperazine, a high-potency phenothiazine antipsychotic dopamine D2 receptor antagonist. See trifluoperazine for complete pharmacological details. This salt formulation provides water-soluble form for oral tablet, liquid, and injectable preparations in schizophrenia and anxiety management.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Trifluoperazine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1257040. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 66064. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.